Recorded live at American Society of Nephrology’s Kidney Week 2025, this episode of Moving Medicine Forward features Courtney Cordaro, Director of Therapeutic Strategy at CTI, and Morgan Terry, Site Director at Eastern Nephrology Associates. Together, they discuss what drives a healthy and productive partnership between clinical research sites and CROs, the critical role of communication, and how both sides can adapt to the evolving landscape of nephrology trials.
01:31 What defines a strong site-CRO relationship
01:49 Key elements of a successful partnership
02:32 The importance of consistency and communication in nephrology research
03:33 How CRO staff changes affect timelines and site efficiency
04:09 Common misconceptions CROs have about sites
05:23 Behaviors and practices that show a CRO’s understanding and build trust
06:31 How an effective CRO response can shape stronger partnerships
07:35 Why minimal turnover and familiarity with site processes are key to building long-term trust
09:05 Adapting to decentralized trials by leveraging strategies for remote monitoring and precision medicine
10:37 Highlighting collaboration and adaptability as keys to success
In this inspiring episode of Moving Medicine Forward,Amanda King, Senior Clinical Scientist at CTI, discusses her remarkable journey from pediatric ICU nurse practitioner to leading-edge oncology researcher. Amanda shares how personal loss fueled her passion for patient-centered careand clinical research, and how her work at the NIH and CTI is shaping the future of medicine. From the complexities of oncology trials to the emotional weight of working with vulnerable patients, Amanda offers a candid look at thechallenges and triumphs of advancing therapeutic options. Whether you're in healthcare or simply curious about the human stories behind medical innovation, this episode is a must-listen.
00:30 Meet Amanda King: her background and passionfor patient-centered care.
01:07 Amanda’s clinical roots in pediatric ICU andtransition to research.
02:00 Pursuing a PhD and discovering a love forclinical trials at the NIH.
02:34 The motivation behind Amanda’s shift toclinical research.
03:34 Why Amanda joined CTI and what drew her toindustry research.
05:10 Amanda’s role as a Senior Clinical Scientistand her impact on trial safety.
06:35 Deep dive into Amanda’s work at the NIH and theimportance of patient outcomes data.
09:21 Challenges in oncology trials: balancingsafety, complexity, and emotional toll.
11:39 The rewards of working in oncology and Amanda’spersonal connection to cancer research.
13:08 Advice for young people interested in clinicalresearch and the importance of mentorship.
15:14 Amanda’s vision for the future of medicine:innovation meets compassion.
16:10 Closing thoughts and how to stay connected withCTI.
Joel White, Owner of Marketcap Consulting, joins another episode to discuss the evolving role of Clinical Research Organizations (CROs). He shares the characteristics of a great CRO, how technology and decentralization are shaping the industry, and the strategic balance between speed, quality, and cost in clinical trials. Whether you're a sponsor, CRO professional, or simply curious about the clinical trial landscape, this episode offers practical wisdom and forward-looking perspectives on drug development and innovation.
00:31 Joel White returns to explore CRO excellence and innovation
01:00 Joel’s background and journey into the CRO industry
01:55 Origins of Joel’s LinkedIn quarterly recaps and their impact
04:10 Defining CROs and their evolving role in clinical trials
05:48 What separates great CROs from average ones, such as customer service and repeat business
08:59 Technology’s role in CRO operations and vendor management
11:29 Balancing speed, quality, and cost in fast-paced trials
12:45 The importance of culture and leadership in CRO success
13:57 Common misconceptions sponsors have about CROs
16:45 Decentralization in clinical trials, including adoption trends and cost tradeoffs
19:05 Evaluating therapeutic area expertise when selecting a CRO
20:46 The future of CROs, consisting of innovation, partnerships, and the potential impact of AI
Chuck Scheper, Board Chair at Bexion Pharmaceuticals, shares how a stage IV non-Hodgkin lymphoma diagnosis at age 39 and a life-saving clinical trial led to his lifelong commitment to cancer research. He joins Tim Schroeder, CEO and Chairman of CTI, to discuss the founding of VaxCella, the evolution of cancer therapies, the importance of patient-centered research, and the role of collaboration in advancing drug development, highlighting resilience, innovation, and the impact of clinical trials.
In this episode, host Jeremy Schrand is joined by Tim Schroeder, Chairman, CEO, and Founder of CTI, and Joel White, Owner of Marketcap Consulting, for a broad discussion on the clinical research industry. Topics include recent industry developments, biotech funding challenges, leadership in clinical trials, corporate citizenship, and predictions for future innovation.
01:20 Tim shares insights on the current state ofthe clinical research industry, highlighting recent developments and a view toward stability and cautious optimism.
02:36 Joe discusses macro trends shaping the clinical research landscape, focusing on biotech funding challenges and the impact on the industry.
04:05 The conversation shifts to the pharma services sector, with Joe reflecting on the changing number of public companies and the influence of major investment firms.
06:53 The conversation explores industry cancellation rates and repeat business, leading to a discussion on measurement differences and the challenges of consistent reporting.
08:08 The role of leadership in navigating today's complex clinical trial environment is explored, emphasizing vision, talent retention, and cultural impact.
13:08 Tim and Joel discuss corporate citizenship, leading to reflections on CTI’s evolution, community involvement, and the importance of sustainability.
21:01 Exploring the potential influence of major retail companies on the clinical trial ecosphere, the conversation considers their resources and the challenges they face within the industry.
22:34 Tim addresses therapeutic areas with recent surges in activity or innovation, prompting a discussion on oncology,neurodegeneration, and GLP therapies.
29:00 Bold predictions shape the future of the clinical research industry, with forecasts pointing to a recovery in biotech funding and shifts in FDA approval processes.
In this special episode, host Jeremy Schrand sits down with Jill Brinck, Executive Director of CancerFree KIDS, and Dr. Genevieve Kendall, a CancerFree KIDS grant recipient and pediatric cancer researcher at Baylor College of Medicine.
Together, they explore the power of early-stage research funding, the challenges and breakthroughs in treating childhood cancers, and the inspiring mission behind CancerFree KIDS. Dr. Kendall shares insights into her lab’s work on fusion-driven rhabdomyosarcoma and how innovative models like transgenic zebrafish are helping uncover new therapeutic targets.
Whether you're a parent, a scientist, or someone passionate about making a difference, this episode offers a compelling look at how collaboration and curiosity are driving real change in pediatric oncology.
Learn more - CancerFree KIDS home page
Learn more about Dr Kendall’s research - Kendall Lab | Nationwide Children's Hospital
Learn more about CTI - CTI - CRO Specializing In Clinical Research And Consulting
02:03 Jill Brink shares her personal and professional journey that led her to become Executive Director of CancerFree KIDS.
04:02 Why funding early-stage, high-risk research is essential for pediatric cancer, highlighting the lack of profitability and federal support in this space.
05:46 Securing funding for early-stage research presents major challenges, including the need for collaboration between scientists and business leaders.
07:06 How CancerFree KIDS selects research projects, outlining the role of their Scientific Advisory Council and the grant scoring process.
09:26 Success stories driven by CancerFree KIDS funding, including early support for clinical trials and advancements in flash proton therapy.
11:22 Dr. Genevieve Kendall explains the nature of fusion-driven rhabdomyosarcoma and why its aggressive behavior and lack of targeted therapies make it difficult to treat.
13:51 How the CancerFree KIDS grant supported a new partnership and provided seed funding to test a promising research idea.
14:50 The significance of identifying HAS3 as a novel target and how it opens new possibilities for treating rhabdomyosarcoma.
16:35 Dr. Kendall describes the role of transgenic zebrafish in her research and how they help uncover therapeutic targets through comparative oncology.
19:33 Both guests share what excites them most about the future of pediatric cancer research, including innovations in CRISPR and immunotherapy.
22:32 How CancerFree KIDS measures the long-term impact of its grants, citing follow-up funding, startup companies, and FDA projects.
24:19 Jill highlights impactful partnerships and community initiatives, such as Jersey Mike’s Day of Giving and the 100-Mile Challenge.
26:15 Details about the 100-Mile Challenge, including its structure and supporting events throughout September.
27:51 How CancerFree KIDS engages with families affected by cancer, ranging from support programs to events that honor children and their journeys.
29:51 The future direction of CancerFree KIDS, including expansion, collaboration, and advocacy efforts with the state of Ohio.
In this episode of Moving Medicine Forward, host Jeremy Schrand welcomes Dr. Rich Curry to discuss how CTI is helping redefine what’s possible in clinical research. From the complexities of cell and gene therapy to the human stories behind the science, Dr. Curry shares how CTI’s expertise in rare diseases and regenerative medicine is accelerating innovation and improving patient outcomes. Discover how CTI’s patient-first approach and global regulatory insight are shaping the future of advanced therapies.
01:03 Dr. Curry explains how his background in neuropsychology and oncology research led him to clinical trials and CTI.
03:08 Dr. Curry highlights why cell and gene therapy excites him, emphasizing its potential to transform treatment approaches.
04:20 He explains how CTI’s full-service research model supports complex, high-risk cell and gene therapy trials.
05:39 Dr. Curry describes the critical safety considerations in cell and gene therapy trials, particularly around immune system risks.
09:31 He explains how CTI approaches long-term follow-up and risk mitigation, sometimes monitoring patients for up to 15 years.
10:51 Dr. Curry shares how CTI stays ahead of global regulatory expectations through its dedicated regulatory and scientific affairs team.
12:03 He gives an example of how CTI helped a sponsor overcome regulatory challenges by identifying risk factors to ensure trial continuation.
13:16 Dr. Curry explains how CTI’s focus on regenerative medicine and rare disease expertise sets it apart in gene therapy support.
14:01 He discusses how CTI’s patient-first philosophy shapes trial design to improve patient experience and trial success.
14:54 Dr. Curry shares excitement for future innovations, especially in treating solid tumors, autoimmune diseases, and neurodegenerative disorders.
17:00 He explains how CTI prepares for the next wave of therapies by building strong sponsor partnerships and providing excellent service.
In this episode of “Moving Medicine Forward,” SavannahDoliboa, Chief Commercial Officer at CTI, shares her career journey and what led her to CTI, a company that combines the strengths of both large and mid-sized CROs. She reflects on the rewards of working with rare disease sponsors, CTI’s diverse client base, and its reputation for flexibility, expertise, and lasting partnerships. Savannah also highlights CTI’s global growth and commitment to advancing clinical research through innovation and collaboration, while navigating regulatory challenges and embracing trends such as AI and patient-centricity.
00:52 Savannah shares her career journey and what led her to join CTI, highlighting her experience at both large and mid-sized CROs and how CTI offered the best of both worlds.
02:39 She discusses what makes working with rare disease sponsors so personally and professionally rewarding, particularly the close connection to patient communities.
03:57 Savannah outlines who CTI’s clients are, explaining that they range from biotech startups to large pharmaceutical companies, with a common thread of complexity and innovation.
04:46 She explains why clients choose CTI, citing the company’s niche expertise, flexibility, and ability to retain skilled team members throughout long and complex trials.
05:48 Savannah talks about how CTI’s agility helps meet client needs, especially when navigating regulatory challenges or changing trial strategies mid-study.
06:33 She identifies current trends in the clinical research industry, such as AI and reducing patient burden, that are creating new opportunities for both CTI and its clients.
07:51 Savannah shares how CTI’s global growth strategy aligns with its mission to go where clients need them most, supported by a strong track record of repeat businessand comprehensive services.
08:56 From a commercial lens, she explains where CTI is headed in the next 3–5 years, emphasizing innovation, quality partnerships, and staying at the forefront of clinical research.
09:33 She sums up why clients choose to work with CTI: a trusted mid-sized partner that delivers global reach, personalized service, and an extensive commitment tobringing treatments to market.
In this episode of “Moving Medicine Forward,” Audrey Davidow shares how her son’s diagnosis led to her co-founding the Pitt Hopkins Research Foundation. She explains the rare genetic disorder, the foundation’s focus on research and family support, and major breakthroughs such as a gene therapy trial. Audrey also reflects on advocacy, leadership challenges, and the hope driving their mission forward.
Support the Pitt Hopkins Research Foundation by visiting PittHopkins.org or donating to the CTI Employee Fund.
01:09 Audrey Davidow shares how her son’s diagnosis led her to co-found the Pitt Hopkins Research Foundation.
02:45 She explains Pitt Hopkins Syndrome as a rare genetic disorder caused by TCF4 gene mutations.
04:35 Audrey recalls the early days of the foundation, driven by grief and an urgent need to act.
06:01 The foundation remains focused on research while still offering family support.
07:54 She highlights major breakthroughs, including a gene therapy trial.
09:41 Funding is directed only to research with a clear path to patient impact.
11:00 Support includes clinics, online communities, and global family conferences.
12:22 Advocacy efforts aim to boost diagnosis rates and raise awareness among medical professionals.
13:12 Challenges include translating science into treatments and navigating leadership without a science background.
14:18 Audrey stays motivated by her son’s resilience and the progress made.
15:31 How grassroots fundraisers have been highly successful.
16:54 Top priorities include launching the gene therapy trial and advancing other genetic treatments.
17:16 She encourages donations and everyday acts of inclusion for those with disabilities.
18:50 Audrey offers a message of hope, emphasizing that meaningful progress is underway.
Alaa Assem, Managing Director for CTI in the Europe & MEA regions, joins us to discuss the evolution of clinical trials in the Middle East and Africa. With over a decade of experience in pharma and CROs, Alaa shares how CTI has built a strong regional presence, the impact of COVID-19, and why sponsors should consider the region for future trials.
Topics Covered:
Timestamps:
In this episode of “Moving Medicine Forward,” Tara Mink,expert in cell and gene therapy for more than 25 years, joins to discuss the science, promise, and challenges of CAR-T therapy. Tara explains how CAR-T works, its remarkable durability, and the side effects clinicians manage. She also discusses the future of gene therapy, barriers to access, and how the field is expanding into new disease areas.
01:05 Tara explains the CAR-T process, including how T cells are collected, genetically modified with a chimeric antigen receptor, expanded, and then reinfused into the patient.
01:49 Discussion of CAR-T’s efficacy, described as both remarkable and durable. It’s positioned as a “one and done” therapy that typically requires no maintenance.
02:30 Tara outlines common side effects like cytokine release syndrome and neurotoxicity, emphasizing their manageability with proper early intervention.
03:18 The future of gene therapy is promising, with projections of 1,500 new therapies emerging by 2030, according to the Cardinal 2025 report.
04:00 Key challenges include the high cost of research and treatment, limited insurance coverage, accessibility to treatment centers, and widespread misinformation in the medical community.
06:37 Solutions include expanding treatment access, supporting outpatient models, partnering with third-party services, and improving insurance and patient education.
09:25 Commercial hurdles are explored, such as the need for better technologies that reduce side effects and the importance of building provider confidence in administering CAR-T in community settings.
10:08 An overview of where CAR-T is headed, including gastrointestinal conditions, prostate cancer, neuroblastoma, lung and breast cancer, and autoimmune diseases.
12:00 Tara shares how patient outcomes have dramatically improved over the last decade, with some blood cancer patients now living 25–30 years post-treatment.
13:06 Encouragement for patients to seek expert guidance, confirm the treatment fits their diagnosis, and work closely with their provider teams for the best path forward.
In this episode of “Moving Medicine Forward,” host Jeremy Strand sits down with Brian Lawrence, Chief Financial Officer at CTI, to explore how strategic financial planning is critical to advancing clinical trials, particularly in rare disease research. Brian shares insights on balancing profitability with purpose in one of the world’s most highly regulated industries, reflecting on early career decisions, global expansion, trial funding challenges, and the growing influence of AI in finance.
00:36
Brian shares how early interests in math and accounting, along with a few great mentors, led him into finance and the clinical research space.
02:17
Why Brian opted for a smaller accounting firm over a Big Four company and how that decision shaped his career.
03:16
How his love for process improvement and early experiences with digital transformation prepared him for the dynamic contract research organization (CRO) environment.
04:03
Brian discusses CTI’s evolution: growing four times in size, expanding globally, and staying true to its rare disease focus.
05:00
The challenge of maintaining profitability while upholding the highest standards in research and compliance.
06:00
Brian explains the hidden costs of operating globally, including banking, compliance, and cybersecurity.
07:10
Why financial planning is critical in biotech, where projects can be halted suddenly due to safety or funding concerns.
09:00
How investment trends and economic shifts post-COVID have tightened budgets and forced CROs and sponsors to adapt.
10:00
Brian breaks down the financial implications of trial diversity, especially in rare diseases with complex study designs.
11:12
The role of AI and digital tools in modern CRO operations, and why CTI is taking a deliberate approach to adoption.
13:00
Brian sees technology as a way to eliminate low-value tasks and empower finance teams to focus on strategic insights.
14:00
Through initiatives like CTI Cares and “Mission Moments,” Brian explains how CTI connects internal teams to the bigger picture of patient impact.
In this episode of Moving Medicine Forward, host Jeremy Schrand sits down with Shawna Bredek, a 20+ year veteran in clinical trial operations, to explore how feasibility assessments shape the future of life-saving research. Shawna shares how her team evaluates sites, navigates post-COVID challenges, tackles regulatory hurdles, and builds lasting relationships that help bring rare disease treatments and transplant innovations to life. Whether you're in clinical research or simply fascinated by medical breakthroughs, this episode offers a powerful look at the strategy behind impactful science.
00:00 – Welcome to Moving Medicine Forward
00:36 – Meet Shawna Bredeck and her background in transplant research
00:52 – What is feasibility and why does it matter?
01:18 – Why choosing the right site and PI is critical
02:12 – Post-COVID challenges: site fatigue, turnover, and timelines
03:34 – Sponsors’ expectations vs. site realities
04:03 – Asking tough feasibility questions upfront
05:17 – Transplant-specific logistics: 24/7 coverage and site readiness
05:54 – Navigating regulatory red tape across countries
07:28 – How regulatory delays can stall important trials
08:12 – Global differences: why it’s easier to start in Brazil than the US
08:54 – Engaging rare disease sites through relationships and reputation
09:56 – Partnering with advocacy groups for trial success
10:58 – Shawna’s proudest career moment: a major transplant drug approval
12:21 – The human side of transplant research
12:50 – Shared mission: patients, sponsors, sites, and scientists
13:02 – Final thoughts and how to connect with CTI
In this episode of Moving Medicine Forward, we sit down with Dr. Helio Tedesco, a globally recognized transplant nephrologist from São Paulo, Brazil, who leads one of the world’s largest kidney transplant programs. Joined by CTI’s Dr. Christopher Boshkos and clinical scientist Erika Aldag, the conversation explores the challenges and innovations behind managing over 15,000 transplant patients, from telehealth expansion and donor matching to cutting-edge immunosuppressive strategies and the future of surveillance tools like cell-free DNA and the iBox model. This episode offers a rare look into the science, systems, and human dedication driving transplant care forward.
00:00 – Introduction
Host Jeremy Strand introduces the podcast and this episode’s focus on transplant innovation.
00:35 – Meet the Guests
Dr. Helio Tedesco (São Paulo), Dr. Christopher Boshkos, and clinical scientist Erika Aldag join to discuss global kidney transplant practices.
01:13 – Dr. Tedesco’s Background
Nearly 40 years in nephrology, performing 1,000+ kidney transplants yearly, with a strong research background.
03:17 – Managing Large Transplant Populations
Insights into follow-up care, decentralized nephrologist networks, and expanding telehealth use.
06:30 – Risk Stratification & Immunosuppression
How patients are matched to regimens, minimizing rejection and addressing regional challenges.
11:49 – Innovations in Induction Therapy
Dr. Tedesco explains their one-dose thymoglobulin approach and its benefits over traditional multi-dose methods.
18:34 – New Tools for Monitoring Graft Health
Use of donor-derived cell-free DNA, biopsy techniques, and barriers to widespread adoption.
24:25 – The iBox Model
Discussion on the potential of iBox as a predictive tool for clinical trials and long-term graft survival.
28:15 – Where Transplant Science Is Headed
Calls for better long-term therapies, biologics, and more patient-friendly immunosuppression options.
32:15 – Telehealth and Outpatient Management
Successes and learnings from scaling telehealth to support a large patient base.
37:41 – Closing Remarks
Appreciation for the collaboration between CTI and global transplant
In this episode of “Moving Medicine Forward” – The Podcast, Jamie Meisenhelder, Chief Administrative Officer (CAO) at CTI, joins us to reflect on her unique journey from law to leadership and how she oversees CTI’s legal, QA, and administrative functions. She shares how her team supports clinical trials, tackles global regulatory challenges, maintains quality standards, and keeps patient trust as the focus. Plus, we explore the future of clinical research and what it takes to stay competitive in an evolving industry.
00:48 Jamie Meisenhelder, CAO of CTI, joins to discuss the roles of QA, legal, and administrative teams.
01:14 Jamie shares her unique path from litigation and finance to joining CTI as a corporate attorney.
01:40 Overview of Jamie's responsibilities: legal, QA, executive admin, and special initiatives.
02:27 How Jamie manages strategic, legal, and QA duties since stepping into the CAO role.
03:15 Her previous experience as Chief of Staff and how it prepared her for broader leadership.
04:07 Strategies for aligning executive leadership and communicating priorities across departments.
05:33 Moving quickly while maintaining quality in contracts and clinical trial agreements.
06:14 Tackling audits, validations, and regulatory demands in global clinical trials.
07:13 CTI’s approach to managing regulations across regions and the role of QA in this evolution.
08:05 Use of SOPs and how consistency is ensured in global projects.
09:27 How a patient-first approach at CTI mitigates legal and reputational risks.
10:06 Jamie reflects on changes in legal and regulatory landscapes during her time at CTI.
11:02 The critical role of confidentiality and how it supports patient trust and sponsor confidence.
12:14 Challenges and opportunities for contract research organizations, focusing on competition, efficiency, and talent retention.
In this episode, Jeremy sits down with Sarah Russo and John DeMarco from Network for Hope, an independent nonprofit organ procurement organization. Together, they explore the life-changing work of organ and tissue donation — from the hospital bedside to the recipient's second chance at life.
Learn how the organization evolved from a merger between LifeCenter and KODA, now serving 7 million people as one of the largest OPOs in the U.S.
00:00 Jeremy introduces the episode and the theme: highlighting breakthroughs in healthcare through the lens of organ donation.
00:36 Sarah Russo (Hospital Partnership Liaison, Network for Hope) and John DeMarco (organ recipient and ambassador) join the conversation.
01:14 Sarah shares her journey from CTI and Cincinnati Children’s to her current role at Network for Hope.
02:19 John reflects on his personal connection as a liver transplant recipient and how clinical trials played a role in his journey.
03:01 The guests discuss how Network for Hope has impacted their lives and shifted their perspectives on organ donation.
04:16 John shares his transplant story, touching on survivor’s guilt and the powerful impact of donation.
06:26 The 2024 merger between LifeCenter and KODA forms Network for Hope — now serving nearly 7 million people.
08:21 Sarah discusses the launch of the first donor care unit in the region, housed in UC’s Flex ICU, and how it's improving organ recovery rates.
11:37 Addressing common misconceptions about donation — from faith concerns to mistrust in hospitals.
14:56 A look at the compassionate approach taken when working with grieving donor families.
15:38 Network for Hope provides six weeks of support followed by a minimum of 18 months through their aftercare team.
17:05 Families participate in honor walks and remembrance ceremonies, recognizing the heroism of donors.
18:11 John shares his unique post-transplant bond with his donor’s family and how they now advocate together.
21:01 Network for Hope encourages transplant recipients to write to their donor families through a new writing station initiative at UC.
23:03 A thoughtful explanation of how donor-recipient relationships are carefully managed and supported.
24:14 Sarah and John share what they look forward to most in April — from flag-raising ceremonies to educational outreach.
26:41 Listeners are encouraged to register as donors, volunteer, and speak to their loved ones about their wishes.
27:56 Network for Hope is spotlighted as CTI’s North American Charity of the Quarter. Closing thanks and resources.
In this episode of “Moving Medicine Forward” – The Podcast, Monica Rodriguez, Managing Director of Global Laboratory, Pharmacometrics, and Site Services at CTI, and Andy Supp, Vice President of Global Laboratory Services at CTI, join the conversation to discuss the unique structure and capabilities of CTI’s global laboratories. They share insights into their respective backgrounds, the strategic importance of CTI’s labs in Cincinnati, OH, and Bilbao, Spain, and how having two lab locations equips CTI with the resources needed to conduct complex clinical trials. The discussion also dives into the benefits these global facilities provide to sponsors conducting clinical trials and the industry at large. Monica also shares her excitement about her new role and the opportunities it presents, while both she and Andy look ahead to the future of CTI and CTI Labs.
0:36 – Introduction of podcast guests: Monica Rodriguez, Managing Director of Global Laboratory, Pharmacometrics, and Site Services, and Andy Supp, Vice President of Global Laboratory Services.
1:03 – Monica shares her background and career journey.
2:08 – Andy shares his background and experience.
3:27 – Discussion on the global lab setup, including CTI’s laboratories in Cincinnati, OH, and Bilbao, Spain.
5:17 – Exploration of how two lab locations benefits sponsors conducting clinical trials and the industry.
6:35 – Monica discusses her new role and the benefits it will bring.
8:54 – A look ahead at what they are most excited about for the future of CTI and CTI Labs.
In this episode of “Moving Medicine Forward” – The Podcast, Pat Dearing, Chief Human Resources Officer at CTI, discusses his career journey and the unique challenges of HR in healthcare. He shares insights on recruiting top talent, "people-first leadership," and CTI's DEIB council. Pat also talks about the future of remote work, HR’s role in acquisitions, and emerging trends shaping the future of HR.
0:23 – Introduction to the podcast guest, Pat Dearing, Chief Human Resources Officer at CTI.
0:40 – Pat shares his career journey and how he discovered CTI.
4:05 – A discussion on the differences and similarities between human resources in healthcare organizations and other industries.
5:19 – Strategies used by CTI HR to recruit top talent for specialized positions.
6:47 – Pat explains what "people-first leadership" means to him.
8:19 – Insights into CTI’s DEIB (Diversity, Equity, Inclusion, and Belonging) council and its progress.
12:42 – Pat’s perspective on the evolving landscape of remote and hybrid work.
14:36 – How Pat manages constant change while focusing on people.
16:15 – What Pat is looking forward to in the future of CTI.
17:20 – How HR plays a role in acquisitions.
18:33 – Trends Pat sees shaping the future of HR.
In this episode of “Moving Medicine Forward” – The Podcast, Christine Eby, Director of Clinical Project Management & Therapeutic Strategy Lead at CTI, Anna Sowa, Chief Mission Officer at CurePDE, Curtis R. Coughlin II, PhD, MS, MBE, Associate Professor, Department of Pediatrics and Center for Bioethics and Humanities, and Kristy McCay, mom of a two-year-old living with pyridoxine-dependent epilepsy (PDE), join together to discuss the ongoing efforts to raise awareness and provide support for those affected by this rare condition. They share insights on the challenges of PDE diagnosis, the importance of newborn screening, and the role of gene editing in treatment. The conversation also explores CurePDE’s advocacy work, its partnerships with organizations like CTI, and the significance of community and patient education in advancing their mission.
0:36 – Introduction of podcast guests: Christine Eby (CTI), Anna Sowa (CurePDE), Dr. Curtis Coughlin II, PhD, MS, MBE, and Kristy McCay (mom of a child with PDE).
1:20 – Overview of CurePDE, a family advocacy organization focused on raising awareness and support for pyridoxine-dependent epilepsy (PDE).
2:29 – Dr. Curtis introduces himself and discusses his involvement with PDE research and the impact of CurePDE’s work in the field.
3:45 – Explanation of PDE from a medical perspective, including common symptoms and challenges faced by patients.
6:40 – Kristy McCay shares her personal journey with her child's PDE diagnosis and the ongoing experience.
7:59 – Kristy reflects on navigating her child’s diagnosis and the challenges of managing a postpartum experience with a new diagnosis.
10:42 – The medical community’s awareness of PDE, including key insights into best practices for diagnosis and treatment.
12:34 – Progress made in advocating for the inclusion of PDE in newborn screening programs.
15:34 – Discussion on a federally recommended panel for states to consider adding to their newborn screening protocols.
16:59 – Lessons other advocacy groups can learn from CurePDE’s work and the importance of understanding each group’s unique journey.
22:06 – How CurePDE is collaborating with organizations like CTI to advance gene editing technology for PDE treatment.
28:06 – Family feedback on gene editing treatments and how families have embraced these new options.
30:44 – The role of organizations like CTI in supporting advocacy groups to further their missions.
36:23 – The significance of community building and patient education in successful advocacy efforts.
41:24 – Activities and support offered to families involved with CurePDE.
43:04 – Advice for other advocacy groups looking to gain recognition and connect with doctors and patients.
44:54 – CurePDE’s fundraising initiatives, where families work together to raise money for the cause.
50:05 – Long-term goals and vision for the future of CurePDE.
In this episode of "Moving Medicine Forward" – The Podcast, Jill Black, Validation IT Principal Auditor at CTI, shares the deeply personal story of her daughter, Emma, and their journey navigating this rare disease. She offers valuable insights into the challenges and impact of Rett Syndrome, while discussing her work at CTI and how being part of an organization focused on rare diseases fuels her hope and purpose. Jill reflects on her experience speaking at the 2024 Rett Syndrome National Summit, supported by NORD, and highlights the critical role of connecting with other parents and advocates. Tune in as Jill explores the exciting progress in Rett Syndrome research, including the FDA-approved drug and the work of pharmaceutical companies aiming to find a cure.
1:19 – Jill shares the powerful story of her daughter, Emma, and her journey with Rett Syndrome, including key insights into the condition and its impact.
6:10 – Jill discusses her role at CTI and how working with an organization that focuses on rare diseases has given her a sense of hope and purpose in making a real difference.
6:33 – Reflecting on her experience speaking at the 2024 Rett Syndrome National Summit, Jill talks about how NORD supported her attendance, enabling her to connect with other parents and advocates in the Rett Syndrome community.
7:50 – After 25 years of research, one FDA-approved drug is available for Rett Syndrome. Jill explains how 20 pharmaceutical companies are currently working to find a cure and the progress being made.
9:00 – Jill shares ways listeners can get involved and support families living with Rett Syndrome.